HIV disclosure and stigma among women living with HIV in Denmark

Maria Wessman1*, Kristina Thorsteinsson1, Merete Storgaard2, Frederikke F Rønsholt3, Isik S Johansen4, Gitte Pedersen5, Lars N Nielsen6, Nina Wies1,7, Terese L Katzenstein3,7 and Anne-Mette Lebech1,7

1 Department of Infectious Diseases, Copenhagen University Hospital Hvidovre, Denmark
2 Department of Infectious Diseases, Aarhus University Hospital, Denmark
3 Department of Infectious Diseases, Copenhagen University Hospital, Denmark
4 Department of Infectious Diseases, Odense University Hospital, Denmark
5 Department of Infectious Diseases, Aalborg University Hospital, Denmark
6 Department of Lung and Infectious Diseases, Nordsjællands Hospital, Denmark
7 Department of Clinical Medicine, University of Copenhagen, Denmark

*Corresponding author: Maria Wessman, Copenhagen University Hospital Hvidovre, Kettegaard Alle 30, 2650 Hvidovre, Denmark
Email: mariajwessman@gmail.com

Abstract

Objective: To identify disclosure, stigma and predictors of non-disclosure among women living with HIV in Denmark.

Methods: A questionnaire study of women living with HIV in Denmark was performed. The enrollment period was from February 2013 to March 2014. Logistic regression was used to estimate predictors of non-disclosure.

Results: A total of 234 participants were included. The majority (94%) had disclosed their HIV status to at least one person outside their healthcare environment, although 29% had disclosed to fewer than three people. Confidantes were mostly partners (96%), siblings (63%), friends (63%) and children (41%). The primary reason for non-disclosure was a feeling that it did not concern others (55%), although reactions upon disclosure were mainly positive in 53%. Predictors of non-disclosure were being of black or Asian ethnicity. Following their HIV diagnosis, 40% no longer dared to have sex, 40% felt isolated and 23% felt that others were afraid and kept a physical distance. In contrast, after disclosure 75% felt better at taking decisions about life and 50% were in closer contact with family and friends.

Conclusion: Almost one-third of participants disclosed their HIV diagnosis to fewer than three people and black or Asian ethnicity predicted non-disclosure. HIV-related stigma regarding sex and contact with others is still highly prevalent; however, reactions to disclosure were mainly positive and associated with secondary positive gains. We strongly urge healthcare professionals to initiate a dialogue regarding stigma and disclosure with women living with HIV with a view to increasing disclosure and minimising stigmatisation in this vulnerable population.

Keywords: HIV, women, disclosure, stigma, black or Asian ethnicity

Introduction

In 2015, 37 million people were living with HIV globally, 51% of whom were women [1]. Within the field of HIV research, there is a profound under-representation of issues relating to women’s health [2] including clinical trials on antiretroviral therapy (ART) [3], sexual and reproductive health, and ageing and psychological well-being [2,4].

One of the key obstacles to HIV treatment, prevention and care is stigma, and most women living with HIV suffer or fear stigmatisation [5–7]. However, in a national Danish survey from 2007 the majority of people living with HIV (PLWH) experienced mostly positive reactions when disclosing their HIV status [8].

HIV stigma is typically divided into three aspects: perceived, experienced or enacted, and internalised stigma [9–11]. Perceived stigma is the awareness among PLWH of negative public attitudes; experienced or enacted stigma includes acts of discrimination towards PLWH; and internalised stigma is the negative belief and feeling towards oneself and HIV.

This study aimed to evaluate disclosure and stigma among women living with HIV in Denmark – a setting where medical care and ART is provided free of charge with a majority of PLWH having fully suppressed plasma viral load [12] and living a ‘close to normal’ life. We further assessed predictors of non-disclosure.
identification number is assigned to each individual, which was used to link to the Danish HIV Cohort Study and the SHADE cohort.

**Danish HIV Cohort Study**

We obtained HIV characteristics and demographics from the Danish HIV Cohort Study, which is a prospective, observational, national, multicentre cohort study of all PLWH seen at Danish HIV clinics since 1 January 1995 (12).

**Ethical statement**

The study was approved by the Danish Data Protection Agency (2015-231-0126, 2012-58-0004 and 2012-41-0005) and the Danish Regional Committee on Health Research Ethics (H-3-2010-119 and H-2-2014-102).

**Statistical analysis**

Categorical variables were reported as counts and percentages and compared by chi-squared tests or Fisher’s exact tests. Continuous variables were summarised as median and interquartile ranges and compared using the Wilcoxon rank-sum test. Univariate and multivariate logistic regression analysis was performed to identify predictors of non-disclosure (defined as disclosure to fewer than three people). Odds ratios and 95% confidence intervals were estimated and adjusted for six candidate predictor variables chosen a priori: age at inclusion (<40 vs ≥40 years of age); ethnicity; latest viral load (<40 vs ≥40 copies/mL); latest CD4 cell count (<350 vs ≥350 cells/μL); time since diagnosis (<10 vs ≥10 years); and educational level (<3 vs ≥3 years after elementary school). To control for repeated testing, a combined P-value was estimated for the ethnicity variable spending more than one degree of freedom in the logistic regression analysis. Individuals with missing explanatory values were excluded from the multivariate regression analyses. The validity of the model was tested using the Hosmer–Lemeshow goodness-of-fit test. SAS statistical software version 9.3 (SAS Institute Inc, NC, USA) was used for data analysis and P<0.05 (two-sided) was considered statistically significant.

**Results**

**Baseline characteristics**

A total of 234 of the 334 women living with HIV in the SHADE study attended the 24-month follow-up (median age was 44 years and median HIV duration was 13 years). Participants were predominantly of white (45%) or black ethnicity (40%) and mostly acquired HIV in Denmark (40%) or Africa (41%). Approximately 80% had a CD4 cell count of >350 cells/μL and the majority (86%) was on ART with an undetectable viral load (<40 copies/mL). Elementary school, which finishes at age 15, was the highest educational level achieved by 24% of the participants (Table 1).

**Disclosure**

Almost all (93.6%) participants had disclosed their HIV status to at least one person (outside the healthcare profession), 34% had disclosed to more than 10 people. However, 6.4% had not disclosed to anyone (Table 2). The participants mostly confided in partners (96%), siblings (63%), friends (63%) and their own children (41%). Reasons for non-disclosure were mainly ‘a feeling that it does not concern others’ (55%), ‘not wanting to be seen as HIV positive’ (46%), and ‘not wanting people to feel sad’ (42%). The majority (88%) had not disclosed their HIV status to people at a current place of work. More than half (53%) of the participants had mainly experienced positive reactions upon disclosure. Black or Asian ethnicities were predictors of non-disclosure (Table 3). The Hosmer–Lemeshow goodness-of-fit tests demonstrated sufficient fit (P=0.087, P=0.052).

**Stigma**

Data from questions about how life and relationships with others had been affected by an HIV disclosure are shown in Table 4. Notably, 40% (total of ‘large’, ‘some’ and ‘small’ extents) of women

**Table 1.** Baseline characteristics of 234 women, living with HIV in Denmark. Median duration of HIV infection was 13 years (IQR 8–18 years) and median age at inclusion was 44 years (IQR 39–51).

| Characteristic | Study participants n (%) |
|---------------|--------------------------|
| Ethnicity     |                          |
| White         | 105 (45.1)               |
| Asian         | 32 (13.7)                |
| Black         | 94 (40.3)                |
| Other         | 2 (0.9)                  |
| Missing       | 1                        |
| Place of HIV transmission |          |
| Denmark       | 84 (39.6)                |
| Europe and USA| 16 (7.6)                 |
| Africa        | 86 (40.6)                |
| Asia          | 26 (12.3)                |
| Other         | 0 (0)                    |
| Missing       | 22                       |
| Mode of transmission |               |
| Heterosexual  | 210 (92.5)               |
| IDU           | 12 (5.3)                 |
| Other         | 5 (2.2)                  |
| Missing       | 7                        |
| Latest CD4 cell count (cells/μL) |         |
| <200          | 11 (5.0)                 |
| 200–350       | 33 (14.9)                |
| >350          | 177 (80.1)               |
| Missing       | 13                       |
| ART           |                          |
| Yes           | 220 (94.0)               |
| No            | 14 (6.0)                 |
| On ART with HIV RNA <40 copies/mL |       |
| Yes           | 182 (85.5)               |
| No            | 31 (14.6)                |
| Missing       | 7                        |
| Educational level |                     |
| Primary or elementary school (age 15 years) | 56 (23.9) |
| Semi-skilled worker training               | 13 (5.6) |
| Apprenticeship or basic vocational training | 19 (8.1) |
| Other vocational training                 | 42 (18.0) |
| Short course of higher education           | 26 (11.1) |
| Medium course of higher education          | 28 (12.0) |
| Long course of higher education            | 14 (6.0) |
| Missing                                    | 36                       |

IDU: intravenous drug use; IQR: interquartile range; ART: antiretroviral therapy.
no longer ‘dared’ to have sex, 40% (total of ‘large’, ‘some’ and ‘small’ extents) felt isolated and 23% thought that others were frightened and kept a physical distance. Half of the participants felt in closer contact with family and friends after disclosure. Following disclosure, 75% (total of ‘large’, ‘some’ and ‘small’ extents) of women felt more empowered when making life decisions. We stratified questions in Table 4 for disclosure status and found that women who had disclosed their HIV status experienced significantly more contact with family and friends and received more care and attention from other people. No differences between groups were found regarding the other questions (data not shown).

**Discussion**

In this questionnaire study on disclosure and stigma among women living with HIV in Denmark who were enrolled into the SHADE study, we found a low level of education in 24% of participants. The vast majority had disclosed their HIV status to at least one person and >50% of women were met with predominantly positive reactions upon disclosure. Furthermore, 75% felt that disclosing improved their ability to make life decisions. However, almost 40% of women felt isolated and 40% no longer dared to have sex. The low level of educational attainment is a cause of concern, since a recent study found that PLWH in Denmark with low educational levels are at increased risk of lifestyle-related mortality as compared to PLWH with higher educational levels [18]. Elementary school is the highest educational level achieved in only 8% of women from the general Danish population (25–69 years) [13].

**Disclosure**

Disclosure is considered to be a gradual process of revealing HIV status to an increasing number of people over time [19]. Disclosure is associated with a better health status, less social isolation and facilitates access to social services and health support [20–22]. The majority of participants had disclosed their HIV status to at least one person. We chose a cut-off of fewer than three people, since confiding in only one or two people reflects a fragile support network. However, almost 30% had disclosed to fewer than three people. Non-disclosure was predicted by black and Asian ethnicity. This was an expected finding, as it is a clear impression in the outpatient clinics that women of African descent experience higher levels of perceived, experienced or enacted, and internalised stigma, compared to their white peers. In line with this, Stutterheim et al. found that fear of stigma was a profound reason of non-disclosure among women.

---

**Table 2. Details of HIV disclosure in 234 women living with HIV in Denmark**

| Question                                                                 | Study participants n (%) |
|--------------------------------------------------------------------------|--------------------------|
| Disclosure overall (other than to healthcare professionals)              |                          |
| Have not told anyone?                                                   | 13 (6.4)                 |
| 1–2 persons                                                             | 46 (22.6)                |
| 3–5 persons                                                             | 45 (22.1)                |
| 6–10 persons                                                             | 31 (15.1)                |
| >10 persons                                                             | 69 (33.8)                |
| Missing                                                                 | 30                       |
| Other than to a healthcare professional, to whom have you disclosed?**   |                          |
| Spouse/partner                                                          | 158 (96.3)               |
| Parents                                                                 | 97 (52.7)                |
| Brothers/sisters                                                        | 116 (63.0)               |
| Own children                                                            | 71 (40.6)                |
| Friends                                                                 | 118 (63.1)               |
| Others                                                                  | 61 (35.1)                |
| Reasons for non-disclosure to the above mentioned people*                |                          |
| You do not feel it concerns them                                        | 46 (54.8)                |
| You are afraid they will blame you for being ill                        | 18 (21.4)                |
| It is a life-threatening illness and you do not want them to be sad     | 35 (41.7)                |
| You are afraid that they will reject you                                 | 29 (34.5)                |
| You do not wish to be seen as someone who is HIV positive               | 39 (46.4)                |
| You are afraid of being talked about behind your back                    | 33 (39.3)                |
| You will tell him/her them at a later time                               | 16 (19.0)                |
| Other                                                                   | 8 (9.5)                  |
| HIV disclosure to people at current place of work*                       |                          |
| Yes, everyone knows                                                     | 9 (5.3)                  |
| Yes, most people know                                                   | 5 (3.2)                  |
| Yes, some people know                                                   | 12 (8.1)                 |
| Yes, your immediate superior knows                                      | 12 (8.7)                 |
| Yes, your immediate colleague knows                                     | 3 (2.2)                  |
| No                                                                      | 119 (87.5)               |
| Reactions of colleagues when being told about the patient’s HIV status   |                          |
| Very positive                                                           | 13 (34.2)                |
| Positive                                                                | 8 (21.2)                 |
| Neutral                                                                 | 6 (15.8)                 |
| Negative                                                                | 0 (0)                    |
| Very negative                                                           | 1 (2.6)                  |
| Both positive and negative                                              | 4 (10.5)                 |
| Do not know                                                             | 6 (15.8)                 |
| Missing                                                                 | 196                      |
| Reactions encountered within the last five years from people around you when revealing the HIV status |                          |
| Mainly positive reactions                                               | 84 (52.5)                |
| Mainly negative reactions                                               | 11 (6.9)                 |
| Reactions have been mixed                                               | 40 (25.0)                |
| Do not know                                                             | 25 (15.6)                |
| Missing                                                                 | 74                       |

* More than one answer is possible; therefore, percentages add up to >100%.
PLWH of African and Afro-Caribbean descent living in the Netherlands [23,24]. Moreover, PLWH who have higher self-perceived HIV-related stigma have been reported to be less likely to disclose their HIV status to partners [25].

Stigma

Participants in the present study showed evidence of perceived stigma, as more than two-thirds stated fear of rejection and of being talked about as reasons for non-disclosure. Experienced stigma was less frequent, although 7% of the participants had encountered negative reactions upon disclosure and 23% felt that others were frightened and kept a physical distance. However, after disclosure, 75% felt better at making life decisions, which implies that disclosure had a positive effect on the participants’ ability to take action regarding life decisions. Internalised stigma was present in almost 30% of participants who felt infectious and kept

| Table 3. Predictors of disclosure of HIV infection in 205 women living with HIV in Denmark, unadjusted and adjusted for: age at inclusion; ethnicity; latest HIV RNA; latest CD4 cell count; time since diagnosis; and educational level |
| Predictors of disclosure | Disclosure to n=2 persons (total number of people=59) n (%) | Disclosure to n=2 persons (total number of people=146) n (%) | Unadjusted odds ratios (95% CI) | P-value | Adjusted odds ratios* (95% CI) | P-value |
|--------------------------|-------------------------------------------------------------|-------------------------------------------------------------|---------------------------------|----------|-----------------------------|---------|
| Age at inclusion (years)  |                                                             |                                                             |                                 |          |                             |         |
| <40                      | 21 (35.6)                                                   | 38 (26.2)                                                   | 1.00 (1.00–1.00)                | 0.10     | 1.00 (1.00–1.00)            | 0.10    |
| ≥40                      | 38 (64.4)                                                   | 107 (73.8)                                                  | 1.56 (0.81–2.98)               | 0.18     | 0.72 (0.31–1.66)            | 0.44    |
| Missing                  | 0                                                          | 0                                                          |                                 |          |                             |         |
| Ethnicity                |                                                             |                                                             |                                 |          |                             |         |
| White                    | 13 (22.8)                                                   | 84 (58.4)                                                   | 1.00 (1.00–1.00)               | 0.10     | 1.00 (1.00–1.00)            | 0.10    |
| Asian                    | 16 (28.1)                                                   | 13 (9.0)                                                    | 0.12 (0.05–0.32)               | <0.0001  | 0.15 (0.05–0.47)            | 0.0011  |
| Black                    | 28 (49.1)                                                   | 47 (32.6)                                                   | 0.26 (0.12–0.55)               | 0.0004   | 0.34 (0.14–0.82)            | 0.017   |
| Missing                  | 2                                                          | 1                                                          |                                 |          |                             |         |
| Combined P-value         |                                                            |                                                             | <0.0001                         | 0.0038   |                             |         |
| Latest viral load (copies/mL) |                                                        |                                                             |                                 |          |                             |         |
| ≥40                      | 9 (17.3)                                                    | 23 (16.5)                                                   | 1.00 (1.00–1.00)               | 0.10     | 1.00 (1.00–1.00)            | 0.10    |
| <40                      | 43 (82.7)                                                   | 116 (83.5)                                                  | 1.06 (0.45–2.46)               | 0.90     | 1.28 (0.51–3.20)            | 0.60    |
| Missing                  | 7                                                          | 6                                                          |                                 |          |                             |         |
| Latest CD4 cell count (cells/μL) |                                                        |                                                             |                                 |          |                             |         |
| <350                     | 8 (15.4)                                                    | 25 (17.9)                                                   | 1.00 (1.00–1.00)               | 0.10     | 1.00 (1.00–1.00)            | 0.10    |
| ≥350                     | 44 (84.6)                                                   | 115 (82.1)                                                  | 0.84 (0.35–1.99)               | 0.69     | 0.98 (0.38–2.50)            | 0.97    |
| Missing                  | 7                                                          | 5                                                          |                                 |          |                             |         |
| Time since diagnosis (years) |                                                        |                                                             |                                 |          |                             |         |
| <10                      | 29 (49.2)                                                   | 50 (34.7)                                                   | 1.00 (1.00–1.00)               | 0.10     | 1.00 (1.00–1.00)            | 0.10    |
| ≥10                      | 30 (50.8)                                                   | 94 (65.3)                                                   | 1.82 (0.98–3.36)               | 0.057    | 1.43 (0.66–3.07)            | 0.36    |
| Missing                  | 0                                                          | 1                                                          |                                 |          |                             |         |
| Educational level        |                                                             |                                                             |                                 |          |                             |         |
| 3 years after elementary school | 40 (75.5)                                                   | 88 (62.0)                                                   | 1.00 (1.00–1.00)               | 0.10     | 1.00 (1.00–1.00)            | 0.10    |
| >3 years after elementary school | 13 (24.5)                                                   | 54 (38.0)                                                   | 1.89 (0.93–3.85)               | 0.080    | 1.24 (0.49–3.19)            | 0.65    |
| Missing                  | 6                                                          | 3                                                          |                                 |          |                             |         |
* Validity of the model was tested using the Hosmer–Lemeshow goodness-of-fit test.

| Table 4. Effect of disclosure on life and relations to others in 234 women living with HIV in Denmark |
|---------------------------------------------------------------|
| Have you experienced:                                        | To a large extent n (%) | To some extent n (%) | To a small extent n (%) | Not at all n (%) | Not sure n (%) | Missing n |
| More contact to family/friends?                               | 31 (16.0)               | 38 (19.6)            | 28 (14.4)               | 81 (41.8)       | 16 (8.2)       | 40        |
| More care/attention from others?                              | 21 (10.9)               | 36 (18.8)            | 31 (16.1)               | 91 (47.4)       | 13 (6.8)       | 42        |
| More consideration towards you?                              | 11 (5.9)                | 20 (10.7)            | 28 (15.0)               | 104 (55.6)      | 24 (12.8)      | 47        |
| That you are better at making life decisions?                 | 59 (30.1)               | 67 (34.2)            | 21 (10.7)               | 36 (18.4)       | 13 (6.6)       | 38        |
| That you feel isolated?                                       | 15 (7.7)                | 33 (16.9)            | 28 (14.3)               | 113 (58.0)      | 6 (3.1)        | 39        |
| That others are afraid/ keep physical distance?               | 7 (3.7)                 | 17 (8.9)             | 20 (10.3)               | 129 (67.2)      | 19 (9.9)       | 42        |
| That you feel infectious/keep distance to others              | 13 (6.7)                | 21 (10.8)            | 23 (11.9)               | 127 (65.5)      | 10 (5.1)       | 40        |
| That you no longer dare to have sex                          | 22 (11.2)               | 24 (12.2)            | 34 (17.3)               | 109 (55.3)      | 8 (4.1)        | 37        |
More than one answer is possible, therefore, percentages add up to >100%.
a distance from others and 40% who no longer ‘dared’ to have sex. In the era of life-saving ART [26] and with recent studies showing negligible or non-existent risk of HIV transmission for PLWH who have chronically fully suppressed plasma viral load [27], internalised stigma needs to be addressed globally in order to decrease both public- and self-stigma, as it is the person living with HIV’s own belief that all the negative assumptions about HIV and themselves are true [28].

The strengths of the present study include the well-described cohort of women living with HIV from the data from the Danish HIV Cohort Study. Furthermore, the use of a validated questionnaire optimised results. An inborn weakness of many questionnaire studies is that answers are self-reported and not objectively verifiable. Data were collected 2013–2014; since then, an improvement in societal perceptions towards a better understanding of HIV and risks of transmission and thereby a reduction in stigma in our patient group is possible. A potential way of determining whether a change in stigma and disclosure has happened would be to repeat the same study, and compare results. We did not take gender-based violence into consideration in this study, which might be a potentially significant issue in our population, particularly when considering disclosure [29,30]. In addition, age may have had an impact on the results, as we expect that older women (who have been diagnosed for a longer period of time than younger women) have experienced more stigma and disclosure issues. They have experienced times when people living with HIV were more stigmatised and discriminated against, than perhaps have younger women. Finally, the exclusion of pregnant women, and alcohol/drug using women may generate results that underestimate the extent of disclosure and stigma among women living with HIV in Denmark.

Conclusion
Perceived, experienced and internalised stigma still remains a burden among women living with HIV in Denmark. Importantly, once HIV status was disclosed, reactions were mainly positive and associated with secondary positive gains. We, therefore, strongly urge healthcare professionals to initiate a dialogue regarding stigma and disclosure with women living with HIV and (if consented by the patient) their networks, as a means to minimise stigmatisation in this vulnerable population. Asking about patient experiences of stigma would enable healthcare professionals to target help and pair patients with mentors who have had similar experiences in the same community. Furthermore, the potential for healthcare professionals to offer education for family members or at the work place, should be explored to increase an understanding of HIV and thereby reduce stigmatisation in patients’ local communities.

Acknowledgements
Conflicts of interest
MW has received an unrestricted grant from Gilead. KT has received research funding from Abbott and honoraria from Janssen-Cilag and GlaxoSmithKline/ViiV. NW has received honoraria from Bristol-Myers Squibb, Gilead, Roche, Janssen, Merck Sharp Dohme and Abbvie. TLK has received research funding/honoraria from Gilead, Bristol-Myers Squibb, Merck Sharp & Dohme, GlaxoSmithKline/ViiV, Abbott, and Janssen-Cilag.

AML has received research funding from Abbott and honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, GlaxoSmithKline, Boehringer Ingelheim and Janssen-Cilag. MS, FFJ, IJ, GP, and LNN report no conflicts of interest.

References
1. UNAIDS. Fact sheet – Latest statistics on the status of the AIDS epidemic, 2016. Available at: www.unaids.org/en/resources/fact-sheet (accessed April 2017).
2. Loufty MR, Sherr L, Sonnenberg-Schwam U et al. Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc 2013, 16: 195059.
3. Soon GG, Min M, Struble KA et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000–2008). AIDS Patient Care STDS 2012, 26: 444–453.
4. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 2005, 28: 1075–1083.
5. Johnson M, Samarria A, Xi H et al. Barriers to access to care reported by women living with HIV across 27 countries. AIDS Care 2015, 27: 1220–1230.
6. Amin A, Baggaley R, Beard J et al. World Health Organization. Consolidated guideline on sexual and reproductive health and rights of women living with HIV, 2017. Available www.who.int/reproductivehealth/publications/gender_rights/srhr-women-hiv/en/ (accessed April 2017).
7. UNAIDS, ICW Global, CNP+. The people living with HIV stigma index. Available at: www.stigmatindex.org/sites/default/files/reports/Michigan%20Stigma %20index%20Report%202016.pdf (accessed June 2017).
8. Castensøn M, Dafæ A. HIV and living conditions—A survey of living conditions and quality of life of people living with HIV in Denmark, 2008. Available at: www.hv-danmark.dk/index.php?id=256 (accessed April 2017).
9. Nyblade LE. Measuring HIV stigma: existing knowledge and gaps. Psychol Health Med 2006, 11: 335–345.
10. Eamshaw VA, Chaudor SR. From conceptualizing to measuring HIV stigma: a review of HIV stigma mechanism measures. AIDS Behav 2009, 13: 1160–1177.
11. Audet CM, McCowan CC, Wallston KA, Kipp AM. Relationship between HIV stigma and self-isolation among people living with HIV in Tennessee. PLoS One 2013, 8: e69564.
12. Obel N, Engsig FN, Rasmussen LD et al. Cohort profile: the Danish HIV cohort study. J Epidemiol 2009, 39: 1203–1206.
13. Statistics Denmark. Folketal-Hovedtæll 2015. Available at: www.dot.dk/en/Statistik/ emner/befolkning-og-valg/befolkning-og-befolkningsfremskrivning (accessed June 2017).
14. Obel N. The National Danish HIV cohort, 2014. Available at: www.nghospitalkontaktet.dk/ afdelinger-og-klinikker/linnen/infektionsevenemerk-nrklinikk/forskning/ Documents/DHK-aarsrapport-2014.pdf (accessed April 2017).
15. Thorsteinsson K, Ladelund S, Storgaard M et al. Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark – the SHADE cohort. BMC Infect Dis 2016, 16: 81.
16. EpilData Association. EpilData software. Available at: www.epildata.com (accessed April 2017).
17. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011, 39: 22–25.
18. Legarth R, Omland LH, Kronborg C et al. Educational attainment and risk of HIV infection, response to antiretroviral treatment, and mortality in HIV-infected patients. AIDS 2014, 28: 387–396.
19. Obermeyer CM, Basij P, Peguni E. Facilitating HIV disclosure across diverse settings: a review. Am J Public Health 2011, 101: 1011–1023.
20. Sowell RL, Seals BF, Phillips KD, Julious CH. Disclosure of HIV infection: how do women decide to tell? Health Educ Res 2005, 18: 32–44.
21. Sayles JN, Wong MD, Kinsler JJ et al. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med 2009, 24: 1101–1108.
22. Geary C, Parker W, Rogers S et al. Gender differences in HIV disclosure, stigma, and perceptions of health. AIDS Care 2014, 26: 1419–1425.
23. Stutterheim SE, Bos AE, Shinpinda I et al. HIV-related stigma in African and Afro-Caribbean communities in the Netherlands: manifestations, consequences and coping. Psychol Health 2012, 27: 395–411.
24. Stutterheim SE, Bos AE, Pryor JB et al. Psychological and social correlates of HIV status disclosure: the significance of stigma visibility. AIDS Educ Prev 2011, 23: 382–392.
25. Przybyla SM, Cohn CE, Widman L et al. Serostatus disclosure to sexual partners among people living with HIV: examining the roles of partner characteristics and stigma. AIDS Care 2013, 25: 556–572.
26. Obel N, Omland LH, Kronborg G et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011, 6: e22698.
27. Rodger AJ, Cambiano V, Bruun T et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016, 316: 171–181.
28. Kalichman SC, Simbayi LC, Cloete A et al. Measuring AIDS stigma in people living with HIV/AIDS: the Internalized AIDS-Related Stigma Scale. AIDS Care 2009, 21: 87–93.
29. Orza L, Bewley S, Chung C et al. ‘Violence: Enough already’: findings from a global participatory survey among women living with HIV. J Int AIDS Soc 2015, 18: 20285.
30. Kennedy CE, Haberstein S, Amin A et al. Safer disclosure of HIV serostatus for women living with HIV who experience or fear violence: a systematic review. J Int AIDS Soc 2015, 18: 20292.